Zobrazeno 1 - 10
of 464
pro vyhledávání: '"K Maman"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Value in Health. 25:S530
Autor:
Jameel Nazir, Richard Zur, Emad Siddiqui, K. Maman, Christopher R. Chapple, Samuel Aballéa, Con Kelleher, Zalmai Hakimi
Publikováno v:
European Urology. 74:324-333
Background Mirabegron is an established treatment alternative to antimuscarinic therapy for patients with overactive bladder (OAB), as shown by efficacy and tolerability data from phase III trials. Objective To assess efficacy and tolerability of mir
Autor:
Jameel Nazir, Con Kelleher, Isaac Odeyemi, Samuel Aballéa, K. Maman, Colette Mankowski, Zalmai Hakimi
Publikováno v:
Neurourology and Urodynamics. 37:986-996
Aims To compare efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents for the treatment of overactive bladder (OAB). Methods Literature searches of MEDLINE, Embase, and the Cochrane Library were undertaken to ident
Autor:
Mohamed-Elmoctar Neine, Jameel Nazir, Isaac Odeyemi, Samuel Aballéa, K. Maman, Zalmai Hakimi, B. Briquet, Andy Garnham
Publikováno v:
Value in Health. 18:783-790
Background Mirabegron, a first-in-class selective oral β 3 -adrenoceptor agonist, has similar efficacy to most antimuscarinic agents and a lower incidence of dry mouth in patients with overactive bladder (OAB). Objectives To evaluate the cost-effect
Autor:
Andy Garnham, K. Maman, Samuel Aballéa, Zalmai Hakimi, Isaac Odeyemi, Mondher Toumi, Jameel Nazir, K. Thokagevistk
Publikováno v:
Clinical Drug Investigation
Background Overactive bladder (OAB) is highly prevalent and is associated with considerable morbidity and reduced health-related quality of life. β3-adrenergic receptor (β3-AR) stimulation is a novel alternative to antimuscarinic therapy for OAB. O
Autor:
Jameel Nazir, Samuel Aballéa, Emad Siddiqui, Isaac Odeyemi, Katia Desroziers, K. Maman, Zalmai Hakimi, Mohamed-Elmoctar Neine
Publikováno v:
European Urology. 65:755-765
Context Overactive bladder (OAB) treatment guidelines recommend antimuscarinics as first-line pharmacologic therapy. Mirabegron is a first-in-class β3-adrenoceptor agonist licensed for the treatment of OAB and has shown to be well tolerated and eff
Publikováno v:
Value in Health. 22:S226
Publikováno v:
Expert Opinion on Pharmacotherapy. 13:9-16
Prolonged-release (PR) melatonin is approved in Europe for the treatment of insomnia in patients aged 55 years and above. The objective of the study was to describe its prescription patterns and its impact on hypnotics use in routine clinical practic
Autor:
Wieczorek, Karina1 (AUTHOR) karina.wieczorek@us.edu.pl, Chłond, Dominik1 (AUTHOR) dominik.chlond@us.edu.pl, Jousselin, Emmanuelle2 (AUTHOR) emmanuelle.jousselin@inrae.fr, Coulson, Stephen J.3 (AUTHOR) stevec@unis.no
Publikováno v:
Zoological Letters. 12/18/2024, Vol. 10 Issue 1, p1-22. 22p.